about
Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategiesA New Scientific Paradigm may be Needed to Finally Develop an HIV VaccineDesigning synthetic vaccines for HIVMechanisms of HIV protein degradation into epitopes: implications for vaccine designHidden memories: frontline memory T cells and early pathogen interceptionA global approach to HIV-1 vaccine developmentComparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vectorImmune-correlates analysis of an HIV-1 vaccine efficacy trialTMEM129 is a Derlin-1 associated ERAD E3 ligase essential for virus-induced degradation of MHC-I.Recent Insights into the HIV/AIDS Pandemic.Immunopathogenesis of simian immunodeficiency virus infection in nonhuman primatesEpithelial stem cells as mucosal antigen-delivering cells: A novel AIDS vaccine approach.Development of replication-competent viral vectors for HIV vaccine delivery.Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens.Estimating the fitness cost of escape from HLA presentation in HIV-1 protease and reverse transcriptase.Immune clearance of highly pathogenic SIV infection.Nonhuman primate models for HIV cure research.Novel vaccine vectors for HIV-1.Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques.HIV-1 Nef sequence and functional compartmentalization in the gut is not due to differential cytotoxic T lymphocyte selective pressure.Lymphocytic choriomeningitis virus persistence promotes effector-like memory differentiation and enhances mucosal T cell distributionB cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllersQuantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine developmentHIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunitySimple mathematical models do not accurately predict early SIV dynamicsWhat Has 30 Years of HIV Vaccine Research Taught Us?Naive T cells are dispensable for memory CD4+ T cell homeostasis in progressive simian immunodeficiency virus infection.Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response.Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome.Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif.Peptide Processing Is Critical for T-Cell Memory Inflation and May Be Optimized to Improve Immune Protection by CMV-Based Vaccine VectorsLymph node T cell responses predict the efficacy of live attenuated SIV vaccines.Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).Neutralizing antibodies to HIV-1 induced by immunization.Broadly targeted CD8⁺ T cell responses restricted by major histocompatibility complex E.IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaquesPotential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved AntigensEfficient mucosal transmissibility but limited pathogenicity of R5 SHIV SF162P3N in Chinese-origin rhesus macaques.Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates.
P2860
Q26825814-C8E54EA6-9C4F-429D-9BED-3010ADB5F262Q26830360-032CBCEB-C824-484B-A945-1C39DF4C54AEQ26862617-36211582-DB44-4A29-B0DC-A58F8B16AF11Q26866505-C954CC7E-1F5E-486E-AD1A-0853DCA5C08EQ27022562-DCB23513-6E83-409C-851B-48C1E5841FF5Q27024614-689113BD-BCB2-4746-B6F1-80C5967DF3AEQ28533970-9051EA08-870F-4CE5-9417-A276A544DA06Q29617377-F35FD197-57E0-4A94-AFE8-EAD4CCE2B07DQ29871423-CCC5DAA2-881F-4505-9D3F-B65C67AA4176Q30235024-7511CA2F-E481-4833-9702-776F77795BF8Q33355730-24AD6444-202D-4260-A0C2-3B7052D77914Q33657468-273513CF-BACD-41DD-AE9D-D26379F026C5Q33694226-0EB19A6F-693A-41D4-9E79-C7E98A9ADCFDQ33887812-0D395032-A26D-4086-827E-921BD71DD67EQ34288751-D0AB8481-9CDE-4064-B35F-92D620D45B36Q34370314-AD18F474-A3EE-446E-B158-8BB61CC266A3Q34407781-642B6511-E6DA-4981-9406-3E7584D1FEFFQ34541191-BE13DB64-FEB1-41B7-9F83-DF291429DD45Q34985353-D644F510-031D-458C-BE08-70CAEF705764Q34995124-1B00DAEF-1405-46EC-A7C5-770EE6429D86Q35005885-4B2C78BD-A8DC-471B-9C0A-7F4ADCF83976Q35058635-6566CB57-9E09-4ED5-BBD1-0B33F3BA40A9Q35072515-F18EFE47-6985-4D74-99A5-D6FB80FF431AQ35108680-7BFE6D8B-9524-4BB2-B730-8B6A6BBA5060Q35232811-08911B42-86C0-4F26-A7E2-8220B80E6A19Q35826634-369704AA-D243-43C9-931E-95B4D5710CBFQ35894221-2E2CD262-B0D3-49A7-8505-921F6DA68B5BQ35993707-063770D9-2019-4BC2-9BFD-494965041C94Q36015624-B69CB360-AB70-4A93-8FDB-C8BFAD85FF9EQ36050577-2F7EAAB6-5621-465A-95FE-EAD7C5B082E7Q36086229-8602CC64-9C4B-419B-A7BC-D2999A7228CEQ36225280-B844DAD0-C3F9-43B7-BE07-B2C2C7ACA8C9Q36385484-1CE93EE1-3FA9-40FB-9E1F-BD30AED4D260Q36495587-D9D2E0D8-DD9C-4B80-836B-C48858883D3EQ36603515-EDAAF3E0-7456-48A6-864F-224EDCFE6C6EQ36624194-09F5F581-1D39-4314-A76C-B01AFD407835Q36694836-92DBF330-E085-44A2-A5B0-985E89191809Q36736400-E4F9E9D8-2C56-42BF-B325-28F45DDBAFC5Q36754296-AE477F97-D20B-47FD-916D-49C100B3A794Q36754331-71CBBB6E-ACF5-4CFD-868D-496251E929C1
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
New paradigms for HIV/AIDS vaccine development.
@ast
New paradigms for HIV/AIDS vaccine development.
@en
type
label
New paradigms for HIV/AIDS vaccine development.
@ast
New paradigms for HIV/AIDS vaccine development.
@en
prefLabel
New paradigms for HIV/AIDS vaccine development.
@ast
New paradigms for HIV/AIDS vaccine development.
@en
P2093
P2860
P1476
New paradigms for HIV/AIDS vaccine development.
@en
P2093
Jeffrey D Lifson
Louis J Picker
Scott G Hansen
P2860
P304
P356
10.1146/ANNUREV-MED-042010-085643
P577
2011-09-19T00:00:00Z